Windward Bio

Executive Summary

Windward Bio is a clinical-stage biotechnology company based in Basel, Switzerland, dedicated to developing novel antibody therapeutics for advanced immunological diseases. The company leverages its expertise in long-acting monoclonal and bispecific antibodies to target validated pathways in respiratory and dermatological conditions. Its lead asset, WIN378, is a long-acting anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody currently in Phase 2 trials for asthma. TSLP is a well-validated target in asthma, and WIN378's extended half-life profile aims to offer less frequent dosing and improved patient convenience, potentially differentiating it from competitors like Tezspire. The company is also exploring WIN378 in other TSLP-driven conditions, including atopic dermatitis and chronic rhinosinusitis with nasal polyps. As a private, early-stage company, Windward Bio faces significant clinical and regulatory risks, but its focus on a proven target with a novel delivery approach positions it well in the competitive asthma biologics market. The company's progress in Phase 2 will be critical for validating its platform and attracting partnership or financing opportunities. With a strong scientific foundation and a clear strategic focus, Windward Bio represents a potential value creator in the immunology space, pending positive clinical data and successful execution of its development plans.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data for WIN378 in asthma60% success
• Q4 2026Initiation of Phase 2 trial for WIN378 in atopic dermatitis50% success
• Q2 2026Series B financing round70% success